focal-therapy

Focal Therapy in Localized Prostate Cancer

What is it

Focal therapy is a growing minimally invasive treatment option for patients with low to intermediate risk prostate cancer that is completely contained (localized) within the prostate. An estimated 1.2 million patients are diagnosed with localized prostate cancer each year in the world (source: WHO Global Cancer Observatory (iarc.fr) . Focal therapy may offer the patients a significant improvement over today’s standard of care.

Today’s standard of care opens for Focal Therapy

Two main approaches to managing localized prostate cancer are today considered as standard of care. The first is the so called “active surveillance”. In these patients, regular tests are performed to monitor the development of the cancer. As long as the cancer is stable, no other actions are taken. If the cancer is starting to spread, treatment will be offered. Of those on active surveillance, about one-third end up needing treatment. Being on active surveillance has shown to be mentally stressful for some patients.

The second approach to managing localized prostate cancer is the use of radiation or surgery. This is effective for removing any tumors present but is typically associated with hard-to-live-with side effects such as loss of control over urinary functions (incontinence) and erectile dysfunction.

Focal therapy offers potential significant advantages over standard of care

Focal therapy offers to preserve these vital functions while still treating the cancer effectively. Focal therapy concentrates on treating “the index lesion,” which is usually defined as a tumor visible on MRI. By removing or controlling the growth of the index lesion with focal therapy, the cancer can be managed safely while minimizing side effects.

In a European Urology consensus meeting, it was agreed, with a high level of consensus, that focal therapy should be recommended for intermediate-risk patients (ref: Donaldson et al, 2015).

Laser ablation in Prostate Focal Therapy

CLS TRANBERG® | Thermal Therapy System (TTT System) is routinely used to provide laser focal therapy of localized prostate cancer. The procedure is minimal invasive and performed at a urology or radiology department. Side effects are minimal and typically the patient can return quickly to normal life. 

Image and needle guidance is used for navigating and positioning the sterile introducer and laser applicator at the correct location in the target tissue, using either the transrectal or transperineal access path. The TTT system can be seamlessly integrated with an existing ultrasound system or MR scanner, with a (stereotactic) needle guide system and a workflow close to that used for targeted biopsies. Our solutions for real time monitoring and control of the procedure enable the physician to personalize and optimize the treatment for each patient.

Contact for more information

Perjan Pleunis
VP Sales Europe
perjan.pleunis@clinicallaser.com

Benefits

Patient in Focus

  • Minimal-invasive procedure allowing the patient to quickly return to normal life and at the same time allowing for more radical treatment option at a later stage, if needed.
  • Low risk of complications – minimal blood loss, low risk of infections, low pain.

Accuracy and Precision

  • Precise positioning of the laser applicator in the defined target area using MRI or ultra-sound fusion for image-guidance.
  • Option to choose between transperineal and transrectal access.
  • Target tissue destruction with high accuracy
  • Surrounding, non-cancerous tissue is spared.

News and insights

28 November, 2022

Clinical data from a Phase II trial using CLS TRANBERG products presented during RSNA 2022 Annual Meeting

The RSNA (Radiological Society of North America) annual meeting is ongoing in Chicago, the US. Yesterday, interim data from the ongoing study in Toronto using CLS´s TRANBERG products, was presented by the principal investigator MD Sangeet Ghai.   

Read more
24 November, 2022

Our CTO Cristina Pantaleone awarded Technician of the Year by the Chamber of Commerce

We are happy to announce that our Chief Technology Officer Cristina Pantaleone today has been awarded Technician of the Year by the Chamber of Commerce and Industry of Southern Sweden.

Read more
8 November, 2022

Scientific presentations related to the use of CLS TRANBERG® products at the 13th iMRI Symposium in Leipzig

We want to highlight a couple of scientific presentations held during the 13th Interventional MRI Symposium 2022 in Leipzig, October 14-15, 2022. This event provides an ideal platform for researchers, clinicians, and healthcare professionals alike to present their latest results within interventional MRI.

Read more

Welcome to Clinical Laserthermia Systems.

Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!


Please choose your country or region

Global
US